Skip to main content
Top
Published in: International Urology and Nephrology 9/2019

01-09-2019 | Nephrology - Original Paper

Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis

Authors: Weiying Li, Yuliang Zhao

Published in: International Urology and Nephrology | Issue 9/2019

Login to get access

Abstract

Purpose

We aimed to evaluate the prognostic value of serum anti-PLA2R and glomerular PLA2R deposit (gPLA2R) in predicting remission of proteinuria in Primary Membranous Nephropathy (PMN) patients.

Methods

PUBMED, EMBASE, WEB OF SCIENCE, COCHRANE LIBRARY and CNKI were searched from 2008 January to December 2018. Heterogeneity was assessed by Cochran Q test and I2. Source of heterogeneity was explored by subgroup analysis and sensitivity analysis.

Results

Totally 2345 patients from 29 cohort studies were eligible for inclusion. The results suggested that PMN patients with negative anti-PLA2R at the time of biopsy had a 1.31 times (95% CI 1.12–1.46, p < 0.05) higher possibility in achieving remission than those with positive anti-PLA2R. The clearance of anti-PLA2R at the end of immunosuppressive therapy showed an even greater chance of achieving remission (RR = 2.86, 95% CI 1.75–4.69, p < 0.05). The relative ratios for complete remission and spontaneous remission with negative anti-PLA2R were 1.65 (95% CI 1.46–1.87, p < 0.05) and 1.93, respectively (95% CI 1.53–2.45, p < 0.05), and heterogeneity percentages were I2 = 18% and 46%, respectively. The possibility for remission was significantly greater among PMN patients with negative gPLA2R (RR = 1.30, 95% CI 1.13–1.50, p < 0.05). Subgroup analyses revealed that retrospective design of study might be the potential source of heterogeneity.

Conclusions

Negative anti-PLA2R or gPLA2R might predict higher possibility of remission, and the presence of anti-PLA2R or gPLA2R might serve as a useful biomarker for clinical outcome and predicting response to immunosuppressive therapy in PMN.
Appendix
Available only for authorised users
Literature
1.
go back to reference Debiec H, Ronco P (2014) Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol 36(4):381–397CrossRefPubMed Debiec H, Ronco P (2014) Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol 36(4):381–397CrossRefPubMed
2.
4.
go back to reference Cattran DC, Brenchley PE (2017) Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int 91(3):566–574CrossRefPubMed Cattran DC, Brenchley PE (2017) Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int 91(3):566–574CrossRefPubMed
5.
go back to reference Li W, Zhao Y, Fu P (2018) Diagnostic test accuracy of serum anti-PLA2R autoantibodies and glomerular PLA2R antigen for diagnosing idiopathic membranous nephropathy: an updated meta-analysis. Front Med (Lausanne) 5:101CrossRef Li W, Zhao Y, Fu P (2018) Diagnostic test accuracy of serum anti-PLA2R autoantibodies and glomerular PLA2R antigen for diagnosing idiopathic membranous nephropathy: an updated meta-analysis. Front Med (Lausanne) 5:101CrossRef
6.
go back to reference Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed
7.
go back to reference Cravedi P, Ruggenenti P, Remuzzi G (2011) Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol 22(8):1400–1402CrossRefPubMed Cravedi P, Ruggenenti P, Remuzzi G (2011) Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol 22(8):1400–1402CrossRefPubMed
8.
go back to reference Hofstra JM et al (2011) Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6(6):1286–1291CrossRefPubMedPubMedCentral Hofstra JM et al (2011) Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6(6):1286–1291CrossRefPubMedPubMedCentral
9.
go back to reference Stahl R, Hoxha E, Fechner K (2010) PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 363(5):496–498CrossRefPubMed Stahl R, Hoxha E, Fechner K (2010) PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 363(5):496–498CrossRefPubMed
10.
go back to reference Gupta G et al (2016) Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clin Transpl 30(4):461–469CrossRef Gupta G et al (2016) Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clin Transpl 30(4):461–469CrossRef
11.
go back to reference Bech AP et al (2014) Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9(8):1386–1392CrossRefPubMedPubMedCentral Bech AP et al (2014) Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9(8):1386–1392CrossRefPubMedPubMedCentral
12.
go back to reference Timmermans SA et al (2015) Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am J Nephrol 42(1):70–77CrossRefPubMed Timmermans SA et al (2015) Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am J Nephrol 42(1):70–77CrossRefPubMed
13.
go back to reference Ruggenenti P et al (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26(10):2545–2558CrossRefPubMedPubMedCentral Ruggenenti P et al (2015) Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26(10):2545–2558CrossRefPubMedPubMedCentral
14.
go back to reference Hofstra JM et al (2012) Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23(10):1735–1743CrossRefPubMedPubMedCentral Hofstra JM et al (2012) Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23(10):1735–1743CrossRefPubMedPubMedCentral
15.
go back to reference Beck LH Jr et al (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22(8):1543–1550CrossRefPubMedPubMedCentral Beck LH Jr et al (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22(8):1543–1550CrossRefPubMedPubMedCentral
16.
go back to reference Kanigicherla D et al (2013) Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83(5):940–948CrossRefPubMed Kanigicherla D et al (2013) Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83(5):940–948CrossRefPubMed
17.
go back to reference Hoxha E et al (2014) M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 9(11):1883–1890CrossRefPubMedPubMedCentral Hoxha E et al (2014) M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 9(11):1883–1890CrossRefPubMedPubMedCentral
18.
go back to reference Song EJ et al (2018) Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy. Kidney Res Clin Pract 37(3):248–256CrossRefPubMedPubMedCentral Song EJ et al (2018) Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy. Kidney Res Clin Pract 37(3):248–256CrossRefPubMedPubMedCentral
19.
go back to reference Hoxha E et al (2014) PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One 9(10):e110681CrossRefPubMedPubMedCentral Hoxha E et al (2014) PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One 9(10):e110681CrossRefPubMedPubMedCentral
20.
go back to reference Hoxha E et al (2015) Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transpl 30(11):1862–1869CrossRef Hoxha E et al (2015) Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transpl 30(11):1862–1869CrossRef
21.
go back to reference Qin HZ et al (2016) Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. J Am Soc Nephrol 27(10):3195–3203CrossRefPubMedPubMedCentral Qin HZ et al (2016) Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. J Am Soc Nephrol 27(10):3195–3203CrossRefPubMedPubMedCentral
22.
go back to reference Jatem Escalante E et al (2015) Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor. Nefrologia 35(5):479–486CrossRefPubMed Jatem Escalante E et al (2015) Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor. Nefrologia 35(5):479–486CrossRefPubMed
23.
go back to reference Kim YG et al (2015) Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy. Am J Nephrol 42(3):250–257CrossRefPubMed Kim YG et al (2015) Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy. Am J Nephrol 42(3):250–257CrossRefPubMed
25.
go back to reference Pourcine F et al (2017) Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS One 12(3):e0173201CrossRefPubMedPubMedCentral Pourcine F et al (2017) Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS One 12(3):e0173201CrossRefPubMedPubMedCentral
26.
go back to reference Timmermans SA et al (2014) Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study. Am J Clin Pathol 142(1):29–34CrossRefPubMed Timmermans SA et al (2014) Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study. Am J Clin Pathol 142(1):29–34CrossRefPubMed
27.
go back to reference Wang Y, Zheng A, Li M (2016) Anti-M-type phospholipase A2 receptor antibody diagnosing and monitoring disease activity in idiopathic membranous nephropathy: a single center and retrospective cohort study. Int J Clin Exp Med 9(12):23351–23362 Wang Y, Zheng A, Li M (2016) Anti-M-type phospholipase A2 receptor antibody diagnosing and monitoring disease activity in idiopathic membranous nephropathy: a single center and retrospective cohort study. Int J Clin Exp Med 9(12):23351–23362
28.
go back to reference Yang Y et al (2016) IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study. Immunol Res 64(4):919–930CrossRefPubMed Yang Y et al (2016) IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study. Immunol Res 64(4):919–930CrossRefPubMed
29.
go back to reference Wei SY et al (2016) Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy. Am J Nephrol 43(2):129–140CrossRefPubMed Wei SY et al (2016) Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy. Am J Nephrol 43(2):129–140CrossRefPubMed
30.
go back to reference Mahmouda RMA, Fayad TM, Hassaballa MA, Sadek KM (2016) Role of anti-phospholipase A2 receptor antibodies in monitoring of the clinical status in idiopathic membranous nephropathy in Egyptian patients. J Egypt Soc Nephrol Transpl 16(4):119–123CrossRef Mahmouda RMA, Fayad TM, Hassaballa MA, Sadek KM (2016) Role of anti-phospholipase A2 receptor antibodies in monitoring of the clinical status in idiopathic membranous nephropathy in Egyptian patients. J Egypt Soc Nephrol Transpl 16(4):119–123CrossRef
31.
go back to reference Ramachandran R et al (2016) Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton) 21(2):139–146CrossRef Ramachandran R et al (2016) Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton) 21(2):139–146CrossRef
32.
go back to reference Wang LJ, Shang MH, Zhuge YF, Huang YX, Rong S, Tang ZH, Bao JF, Yu Q, Yuan WJ (2016) Expression of renal PLA2R in patients with idiopathic membranous nephropathy and its relationship with the curative effect of immunotherapy. Natl Med J China 96(1):4–8 Wang LJ, Shang MH, Zhuge YF, Huang YX, Rong S, Tang ZH, Bao JF, Yu Q, Yuan WJ (2016) Expression of renal PLA2R in patients with idiopathic membranous nephropathy and its relationship with the curative effect of immunotherapy. Natl Med J China 96(1):4–8
33.
go back to reference Zhang Y, Yuan L (2017) The significance of anti-PLA2R antibody for the diagnosis and treatment of idiopathic membranous nephropathy. Int J Urol Nephrol. 37(6):896–899 Zhang Y, Yuan L (2017) The significance of anti-PLA2R antibody for the diagnosis and treatment of idiopathic membranous nephropathy. Int J Urol Nephrol. 37(6):896–899
34.
go back to reference Zhou G, Guo Y, Zhang L, Wang X, Wu C (2016) Curative efficacy of tacrolimus combined with corticosteroids in treatment of idiopathic membranous nephropathy and response of anti-M-type phospholipase A2 receptor antibody to treatment. J Jilin Univ (Medicine Edition) 42(5):937–941 Zhou G, Guo Y, Zhang L, Wang X, Wu C (2016) Curative efficacy of tacrolimus combined with corticosteroids in treatment of idiopathic membranous nephropathy and response of anti-M-type phospholipase A2 receptor antibody to treatment. J Jilin Univ (Medicine Edition) 42(5):937–941
35.
go back to reference Xu Y, Sun X, Zou Y, Cui D, Wu X (2017) Expression of serum anti-phospholipase A2 receptor antibodies in patients with idiopathic membranous nephropathy and its relationship with the effect of immunotherapy. Henan Med Res. 26(12):2119–2122 Xu Y, Sun X, Zou Y, Cui D, Wu X (2017) Expression of serum anti-phospholipase A2 receptor antibodies in patients with idiopathic membranous nephropathy and its relationship with the effect of immunotherapy. Henan Med Res. 26(12):2119–2122
36.
37.
go back to reference Liu H et al (2016) Detection and clinical significance of glomerular M-type phospholipase A2 receptor in patients with idiopathic membranous nephropathy. Intern Med J 46(11):1318–1322CrossRefPubMed Liu H et al (2016) Detection and clinical significance of glomerular M-type phospholipase A2 receptor in patients with idiopathic membranous nephropathy. Intern Med J 46(11):1318–1322CrossRefPubMed
38.
go back to reference Wang J et al (2017) Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study. BMC Nephrol 18(1):227CrossRefPubMedPubMedCentral Wang J et al (2017) Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study. BMC Nephrol 18(1):227CrossRefPubMedPubMedCentral
39.
go back to reference Xu NX et al (2017) Renal phospholipase A2 receptor and the clinical features of idiopathic membranous nephropathy. Chin Med J (Engl) 130(8):892–898CrossRef Xu NX et al (2017) Renal phospholipase A2 receptor and the clinical features of idiopathic membranous nephropathy. Chin Med J (Engl) 130(8):892–898CrossRef
40.
go back to reference Ding L, Yu M, Peng J, Wu L (2015) The clinical significance of combined staining of anti-PLA2R antibody with IgG4 in patients with idiopathic membranous nephropathy. J Ningxia Med Univ 37(11):1256–1260 Ding L, Yu M, Peng J, Wu L (2015) The clinical significance of combined staining of anti-PLA2R antibody with IgG4 in patients with idiopathic membranous nephropathy. J Ningxia Med Univ 37(11):1256–1260
41.
go back to reference Ling YQ et al (2017) The association between PLA2R expression in kidney tissue of patients with idiopathic membranous nephropathy and response to immunosuppressive therapy. Shandong Med 57(27):79–81 Ling YQ et al (2017) The association between PLA2R expression in kidney tissue of patients with idiopathic membranous nephropathy and response to immunosuppressive therapy. Shandong Med 57(27):79–81
Metadata
Title
Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis
Authors
Weiying Li
Yuliang Zhao
Publication date
01-09-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 9/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02147-9

Other articles of this Issue 9/2019

International Urology and Nephrology 9/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.